Almirall
Sociedad Anónima | |
BMAD: ALM | |
ISIN | ES0157097017 |
Founded | 1943 |
Founder | Antonio Gallardo Carreras |
Headquarters | |
Area served | International |
Products | Ebglyss, Ilumetri, Wynzora, Klisyri, Seysara, Ebastel, Monodox, Acticlate, Almogran, Tesavel & Efficib, Solaraze, Airtal, Decoderm, Cordran, Almax, Parapres, Balneum, Sativex, Cleboril, Monovo, Actikerall.[1] |
Revenue | €878.5 million (2022)[2] |
€33.5 million (2022)[2] | |
Total assets | €2.302 billion (2022)[2] |
Number of employees | 1,800 (2022)[3] |
Website | www |
Almirall, S.A. is a Spanish
In 2016, it generated total revenue of
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and United States.
History
Early history
Almirall SA was founded in 1943 in Spain. In 1979, the company launched gastroprokinetic clebopride in Spain, the first product from the company’s internal R&D team. In 1984, the business launched antacid product, almagate, in Spain, as well as anti-inflammatory piketoprofen in 1985 and antihistamine ebastine and cinitapride in 1985. In the same year, Almirall opened its first subsidiary, based in Belgium. In 1992 the company launched aceclofenac and a year later opened its second foreign subsidiary, in Portugal. The company's new headquarters were opened in Barcelona, in 1994. In 1997 Almirall and Prodesfarma merged their interests.[citation needed]
Further expansion
In 2000 the FDA approved anti-migraine agent almotriptan. A year later the company opened its Mexican subsidiary as well as acquiring its French affiliate. Beginning in 2002, Almirall opened a series of European based subsidiaries; Italy (2002), Germany (2003), Austria, Poland, the United Kingdom, Ireland and Switzerland (2008) and Nordic Countries (2010).[6]
In 2005 the business acquired the commercial rights for
In 2007, the company floated on the Spanish stock market, as well as acquiring European dermatology specialist, Hermal. The company also acquired a portfolio of eight products from
In 2011, Almirall launched Actikerall prescribed for the local treatment of actinic keratosis.
In 2012, Almirall opened its first North America subsidiary, based in Canada
In 2013 Almirall acquired another specialist dermatology company, Aqua Pharmaceuticals. The company launched linaclotide in Europe (Constella) for irritable bowel syndrome with constipation (IBS-C) and opened its Netherlands subsidiary.[6]
In 2014 Almirall divested its rights to its respiratory franchise to Astrazeneca focussing on the dermatology, later in 2015 declaring its strategic intention to become a leading pharmaceutical company in the field of dermatology and continuing with its expansion by acquiring Poli Group Holding.
In 2016 Almirall acquired ThermiGen LLC.[7]
In January 2020, the company announced it would acquire Bioniz Therapeutic.[8][9] In 2020, Almirall earned 74.3 million euros, 30% less than the previous year. The following year it closed with a loss of 40.9 million. According to the annual accounts, the losses were justified by the accounting impairment of various products, although sales grew by 2.5%, driven by the dermatology business. In February 2022 it was announced that Carlos Gallardo would replace his father, Jorge Gallardo, as president of the company.[10]
Activities
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (
Centres
The company has three
The company also has three production centres: two in Spain, the pharmaceutical plant in Sant Andreu de la Barca (Barcelona) and the pharmaceutical and chemical plant in Sant Celoni (Barcelona); and a pharmaceutical plant in Germany (Reinbek); as well as 13 affiliates in Germany, Austria, Belgium-Luxembourg, the United States, France, the Netherlands, Italy, the Nordic countries, Poland, Portugal, the United Kingdom-Ireland, Spain, and Switzerland.[13]
Numbers
2010 | 2011 | 2012 | 2013 | 2014 [14] | 2015 [15] | 2016 [5] | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total revenue | €1002,1 MM | €873,1 MM | €900,2 MM | €825,5 MM | €1.407,4 MM | €769 MM | €859,3 MM | €755,8 MM | €811,0 MM | €908,4 MM | €814,5 MM | €836,5 MM | €878,5 MM |
Net sales | €882.4 MM | €768.4 MM | €682.9 MM | €692.9 MM | €786.4 MM | €685 MM | €764,4 MM | €639,4 MM | €756,9 MM | €853,1 MM | €807,4 MM | €827,2 MM | €863,2 MM |
% International sales | - | 50% | 60% | 62% | 70% | 68% | 70% | 69% | |||||
% Sales of own medicines | - | - | 59% | 64% | 70% | 67% | 77% | 68% | |||||
Investment in R&D [16] | 16.4% of net sales | 18.8% of net sales | 23.4% of net sales | 18% of net sales | 12.8% of net sales | 9.7% of net sales | 12,9% of net sales | 13,7% of net sales | 11,6% of net sales | 10,8% of net sales | 10% of net sales | 9% de of net sales | 12% of net sales |
Employees | 2,831 | 2,765 | 2,871 | 3,000 | 2,100 | 1,889 | 1,975 | 1.832 | 1.805 | 1.765 | 1.785 | 1.786 | 1.845 |
Affiliates | 13 | 13 | 14 | 15 | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 |
R&D Centres [17] | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 1 |
Production centres | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 |
Main products
Brand | Active ingredient | Pathology |
---|---|---|
Ebastel | Ebastine | Allergy |
Monodox | Doxycycline | Severe Acne |
Acticlate | Doxycycline hyclate | Severe Acne |
Almogran | Almotriptan | Migraine |
Tesavel and Efficib | Sitagliptin and sitagliptin/metformin | Diabetes |
Solaraze | Diclofenac sodium | Actinic keratosis |
Airtal | Aceclofenac | Musculoskeletal pain |
Decoderm | Fluprednidene | Fungal dermatitis |
Cordran | Fludroxycortide | Inflammation and itching of the skin |
Parapres | Candesartan | Hypertension |
Almax | Almagate | Acidity |
Balneum | Urea | Dry skin |
Cleboril | Clebopride | Gastroesophageal reflux disease |
Actikerall | 5-Fluorouracil / salicylic acid |
Actinic keratosis |
Sativex | Nabiximols | Spasticity in Multiple Sclerosis |
Monovo | Mometasone | Psoriasis |
Ilumetri | Tildrakizumab | Psoriasis |
Ebglyss | Lebrikizumab | Atopic Dermatitis |
Wynzora | Calcipotriol/Betamethasone | Psoriasis |
Klisyri | Tirbanibulin | Actinic keratosis |
Seysara | Sarecycline | Acne |
Physiorelax | Helenalin | Muscle and ligament massage |
References
- ^ Products «Products of Almirall S.A. Archived 5 September 2014 at the Portuguese Web Archive» Retrieved 17 December 2014
- ^ a b c {{cite web|url=https://www.cnmv.es/portal/consultas/ifa/listadoifa.aspx?id=0&nif=A-58869389&lang=en
- ^ "Almirall Annual Report 2019". Almirall. Archived from the original on 2 August 2021. Retrieved 1 December 2020.
- ^ "Almirall | About Almirall | History". www.almirall.com. Archived from the original on 29 September 2018. Retrieved 31 May 2023.
- ^ a b www.almirall.com https://www.almirall.com/documents/10876/201201/170224_FY16_FR_English.pdf. Retrieved 31 May 2023.
{{cite web}}
: Missing or empty|title=
(help) - ^ a b c "Archived copy". www.almirall.com. Archived from the original on 2 August 2021. Retrieved 31 May 2023.
{{cite web}}
: CS1 maint: archived copy as title (link) - ^ "Almirall Closes The Acquisition Of ThermiGen LLC Entering The Aesthetics Market". BioSpace. Archived from the original on 2 March 2023. Retrieved 2 March 2023.
- ^ "Almirall enters into an option agreement to acquire Bioniz Therapeutics and to establish a broad research agreement to further expand its innovative pipeline in medical dermatology". BioSpace.
- ^ "Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases". BioSpace.
- S2CID 243137601.
- ^ "Home". Parc Científic de Barcelona (in Catalan). 10 August 2020. Archived from the original on 10 May 2023. Retrieved 31 May 2023.
- ^ "Esborrany automàtic – BRN" (in Catalan). Archived from the original on 26 March 2023. Retrieved 31 May 2023.
- ^ "Almirall Media | FAQs". www.almirall.com. Archived from the original on 26 October 2016. Retrieved 31 May 2023.
- ^ "Archived copy" (PDF). www.almirall.com. Archived (PDF) from the original on 9 March 2016. Retrieved 31 May 2023.
{{cite web}}
: CS1 maint: archived copy as title (link) - ^ "Archived copy" (PDF). www.almirall.com. Archived (PDF) from the original on 17 June 2016. Retrieved 31 May 2023.
{{cite web}}
: CS1 maint: archived copy as title (link) - ^ Partnering and Collaboration «Partnering and Collaboration Archived 5 September 2014 at the Portuguese Web Archive» Retrieved 18 December 2014
- ^ R&D in Key Therapeutic Areas «R&D in Key Therapeutic Areas Archived 18 December 2014 at archive.today» Retrieved 18 December 2014